Nimbus Therapeutics LLC has disclosed 15-hydroxyprostaglandin dehydrogenase inhibitors reported to be useful for the treatment of alopecia, muscle atrophy and more.
Immune checkpoint blockade is one of the major advances in cancer treatment in recent years. However, the majority of immune checkpoints are embedded in the cell membrane and this fact represents a limitation for targeted degradation using proteolysis-targeting chimeras (PROTACs).
Neuroinflammation is a key feature of Alzheimer’s disease (AD). The activation of the NLRP3 inflammasome has been associated with the pathogenesis of AD, therefore, targeting NLRP3 may help reduce neuroinflammation and slow down the progression of AD.
CSPC Pharmaceutical Group Ltd.’s antibody-drug conjugate SYS-6045 has been granted clearance by China’s National Medical Products Administration (NMPA) to enter clinical trials.
A €20 million (US$20.6 million) series A financing round at Neumirna Therapeutics ApS is set to support the company’s development of RNA therapies for epilepsy, Parkinson’s disease and other neurological disorders, and enable the company to advance its lead asset into the clinic.
Researchers from Gazi University and Friedrich-Schiller-Universität Jena presented the discovery and preclinical characterization of novel microsomal prostaglandin E2 synthase 1 (mPGES-1) inhibitors as potential anti-inflammatory and analgesic drug candidates.
RSS
